ArticleBMC musculoskeletal disorders2026
A novel endoscopic retroperitoneal approach for debridement in lumbar infectious spondylodiscitis at L4-5: a clinical series and technical note.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe L4-5 is one of the most commonly affected levels in lumbar infectious spondylodiscitis. Surgical intervention is typically required when conservative antibiotic therapy fails. For patients with extensive anterior abscess formation or widespread lesions, an anterior approach is often necessary. However, at the L4-5 level, the dense distribution of the lumbar plexus and the close proximity of the iliac vessels to the lesion demand particular caution when selecting an anterior approach. The present study aims to evaluate the feasibility, safety, and preliminary clinical efficacy of a novel endoscopic retroperitoneal approach for debridement combined with posterior percutaneous pedicle screw fixation in the treatment of lumbar infectious spondylodiscitis at the L4-5 level.
methodsThis retrospective study analyzed patients with L4-5 lumbar infectious spondylodiscitis who underwent endoscopic retroperitoneal debridement at our institution between July 2022 and July 2024. Baseline patient characteristics, operative time, intraoperative blood loss, postoperative lesion clearance, changes in inflammatory markers(e.g, C-reactive protein[CRP] and erythrocyte sedimentation rate[ESR]), complication rates, Visual analog scale (VAS) scores for back pain, Oswestry Disability Index (ODI) scores, kyphotic angle changes at the infected level, and radiological follow-up outcomes were recorded.
resultsOf the 28 patients, 27 (27/28, 96.43%) showed improvement in clinical symptoms. During follow-up, all patients demonstrated significant improvements in VAS scores and ODI scores compared to preoperative values (p<0.05). At the final follow-up, all patients exhibited a kyphotic angle change of less than 8°, and no spinal instability was observed. Computed tomography (CT) at the 12-month follow-up demonstrated intervertebral bone fusion in 26 cases (26/28, 92.86%). Postoperative inflammatory markers showed improved compared with preoperative levels (p<0.001). No infection recurrence or serious surgery-related complications were observed during the postoperative follow-up period.
conclusionEndoscopic retroperitoneal debridement combined with posterior percutaneous pedicle screw fixation appears to be a safe and effective minimally invasive approach for treating L4-5 lumbar infectious spondylodiscitis. However, long-term efficacy requires further validation through prospective studies with larger sample sizes and extended follow-up periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.